Loi, Sherene

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

Dushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A., Luen, S. J., Mansour, M., Kershaw, M. H., et al. (2017) · Nature Communications

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 124

Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

Rugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiss, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M., et al. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 116

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Brufsky, A., Kim, S. B., Zvirbule, Ž., Eniu, A., Mebis, J., Sohn, J. H., Wongchenko, M., Chohan, S., Amin, R., Yan, Y., et al. (2021) · Annals of Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 92

Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells

Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 68

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

Cristofanilli, M., Rugo, H. S., Im, S.-A., Slamon, D. J., Harbeck, N., Bondarenko, I., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., et al. (2021) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 65

Improved treatment of breast cancer with anti-HER2 therapy requires interleukin-21 signaling in CD8+ T cells

Mittal, D., Caramia, F., Michiels, S., Joensuu, H., Kellokumpu-Lehtinen, P.-L., Sotiriou, C., Loi, S., & Smyth, M. J. (2016) · Cancer Research

HER2/EGFR in Cancer ResearchCancer Immunotherapy and Biomarkers

Cited by 27

Efficacy and safety of immune checkpoint blockade in patients with Li-Fraumeni syndrome

Bottosso, M., Verret, B., Caron, O., Hamzaoui, N., Pasmant, E., Danlos, F.-X., Boudou-Rouquette, P., Srikaran, A., Blons, H., Guarneri, V., et al. (2024) · JCO Precision Oncology

Cancer Immunotherapy and BiomarkersImmunodeficiency and Autoimmune Disorders

Cited by 6